Given that ANLN and ECT2 have been demonstrated to tightly regulate cytokinesis and actin organization via the RhoA/ROCK pathway [45], the potential of targeting the ANLN, ECT2, and/or the ANLN–ECT2 complex in patients with advanced PCa warrants further investigation. The gene discussed is ANLN; the disease is posterior cortical atrophy.